Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI

Steffen Wolfsgruber1, Frank Jessen2, Alexander Koppara2

  • 1From the Department of Psychiatry (S.W., F.J., A. Koppara, L.K., W.M., M.W.), University of Bonn; German Center for Neurodegenerative Diseases (S.W., F.J. A. Koppara, L.K., W.M., M.W.), Bonn; Center for Geriatric Medicine (K.S.), Ortenau Klinikum, Offenburg-Gengenbach; Department of Gerontopsychiatry (L.F.), Central Institute of Mental Health, Mannheim; Department of Psychiatry (A. Kurz), Technical University of Munich; Department of Neurology (S.S.), University of Aachen; Department of Psychiatry and Psychotherapy (S.S., E.R., J.W.), University of Göttingen, Germany; AXA Research Fund & UPMC Chair Sorbonne Universités (H.H.), Université Pierre et Marie Curie, Paris; Institut de la Mémoire et de la Maladie d'Alzheimer (H.H.), Département de Neurologie, Hôpital de la Pitié-Salpétrière, Paris; INSERM U1127 (H.H.), Institut du Cerveau et de la Moelle épinière, Paris, France; Department of Psychiatry (I.H., O.P., F.M.R.), Charité Berlin, Campus Benjamin Franklin, Berlin; Department of Psychiatry (H.J.), University of Hamburg; Department of Psychiatry (C.L.), University of Düsseldorf; Center for Geriatric Medicine and Gerontology (M.H.), University of Freiburg; Department of Psychiatry (H.-J.G.), University of Leipzig; Department of Psychiatry (J.S.), University of Heidelberg; Department of General Medicine (J.P.), University of Frankfurt, Frankfurt am Main; Department of Medical Informatics (O.R.), University of Göttingen, Germany; Brookhaven National Laboratory (F.H.), Upton, New York; and Department of Psychiatry (J.K.), Friedrich-Alexander University Erlangen, Germany. F.J. is currently with the Department of Psychiatry, University of Cologne. steffen.wolfsgruber@ukb.uni-bonn.de.

Neurology
|February 27, 2015
PubMed
Abstract

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
730
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K